Is antiviral treatment (IFNα and/or ribavirin) justified in cirrhosis related to hepatitis C virus?

Acta Gastro-Enterologica Belgica

Volumn 61, Issue 4, 1998, Pages 431-437

  Poynard, T ^a   Moussalli, J ^a   Ratziu, V ^a   Thevenot, T ^a   Regimbeau, C ^a   Opolon, P ^a   Horsmans, Y ^a   Brenard, R ^a   Closon, M ^a   Fevery, J ^a   Hautekeete, M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cost effective strategy; Empirical therapy; Endoscopy; Gastro oesophageal reflux disease; Proton pump inhibitors; Therapeutic trial

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; BLOOD CELL COUNT; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INCIDENCE; META ANALYSIS;

ANTIVIRAL AGENTS; BELGIUM; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; META-ANALYSIS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032432551     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)